Skip to main content
Equibles
LENZ logo

LENZ · LENZ Therapeutics, Inc.

Track LENZ — free

Use LENZ with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LENZ

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.73 +0.13 (+2.83%) At close · Aug 14
Market Cap
$148.62M
Shares
31.42M

LENZ Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for LENZ Therapeutics, Inc. (LENZ) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$10.25M '24 Q2 24-08-14 · $ −$10.21M '24 Q3 24-11-06 · $ −$14.62M '25 Q1 25-05-07 · $12.50M −$16.70M '25 Q3 25-11-05 · $1.59M −$35.90M '25 Q4 26-03-24 · $1.90M −$41.49M '26 Q1 26-05-11 LATEST ▲9.7% $5.49M −$31.92M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
LENZ Therapeutics, Inc. Q2 FY2026 Earnings Call
Positive tone Telehealth access initiative Patient persistence and refills July launch momentum
Revenue
$5.49M
▲ 9.7% YoY
Diluted EPS
$-1.02
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
LENZ Therapeutics, Inc. Q1 FY2026 Earnings Call
Positive tone Real-world efficacy and prescriber experience Launch adoption pacing R&D spending going to zero
Revenue
$1.90M
Diluted EPS
$-1.32
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
LENZ Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone Launch traction and prescriber base Direct-to-consumer campaign Patient persistence and refills
Revenue
$1.59M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-03-10
Leerink Partners 2026 Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-02
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-05
LENZ Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone VIZZ commercial launch and early prescription uptake Distance vision benefit and potential label expansion Sales force deployment and optometry/ophthalmology targeting
Revenue
$12.50M
Diluted EPS
$-0.59
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
LENZ Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone Commercial readiness and launch pillars Patient/DTC awareness and sampling LNZ100 regulatory progress and PDUFA
Revenue
$
Diluted EPS
$-0.53
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-19
LENZ Therapeutics, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
LENZ Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone LNZ100 regulatory progress and PDUFA timeline Commercial preparation and market opportunity Competitive positioning versus pilocarpine/VUITY
Revenue
$
Diluted EPS
$-0.38
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
LENZ Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone NDA submission and FDA regulatory pathway Phase 3 CLARITY trial results for LNZ100 Use patterns among eye care professionals
Revenue
$
Diluted EPS
$-0.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
LENZ Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone CLARITY Phase 3 trial results for LNZ100 Discontinuation and patient interest survey results NDA submission and regulatory pathway
Diluted EPS
$-3.53
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts CIK 1815776 CUSIP 52635N103 13F (30d) 139 filings 138 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)